表紙
市場調查報告書

治療抵抗性憂鬱症 (TRD):流行病學的預測 (到2030年)

Treatment-resistant depression (TRD) - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 948136
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
治療抵抗性憂鬱症 (TRD):流行病學的預測 (到2030年) Treatment-resistant depression (TRD) - Epidemiology Forecast - 2030
出版日期: 2020年06月01日內容資訊: 英文 100 Pages
簡介

全球主要7個國家的治療抵抗性憂鬱症 (TRD)的已受診患者數,2017年達到了4,464,781人。其中,美國國內已受診患者數成為3,083,238人。

本報告提供全球主要國家 - 美國、歐洲主要5個國家 (EU5:法國、德國、義大利、西班牙、英國) 、日本 - 的治療抵抗性憂鬱症 (TRD)的流行病學趨勢與今後的預測分析。

第1章 主要考察

第2章 治療抵抗性憂鬱症 (TRD):概要

  • TRD的患者數佔有率 (2017年)
  • TRD的患者數佔有率 (2030年)

第3章 組織

第4章 摘要整理

第5章 疾病概要:治療抵抗性憂鬱症 (TRD)

  • 簡介
  • 症狀
  • 疾病和風險因素
  • 憂鬱症的病理生理學
  • 主要的憂鬱症性障礙的遺傳性根據
  • 治療抵抗性憂鬱症:病期分類
  • 診斷
    • DSM (精神疾病診斷、統計的指南)
    • 大憂鬱症性障礙的DSM-IV-TR標準
    • DSM-V:診斷標準-大憂鬱症性障礙
    • 診斷功能
    • 鑑別診斷
    • 大憂鬱症性障礙的診斷標準:ICD-10依據

第6章 流行病學和患者人口

  • 主要調查結果
  • 治療抵抗性憂鬱症 (TRD)的患病者、患者總數 (主要7個國家的情況)
  • 治療抵抗性憂鬱症 (TRD):各國流行病學的趨勢
  • 美國
    • 假設和根據
    • TRD的已受診患病者總數
    • TRD的已受診患病人數:男女
    • TRD的已受診患病人數:各年齡
  • (EU5歐洲主要5個國家)
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第7章 目前治療慣行

  • TRD的治療策略
  • NICE的指南:成人憂鬱症的治療和管理
  • 法國臨床指南:治療抵抗性憂鬱症

第8章 未滿足需求

第9章 SWOT分析

第10章 案例研究

第11章 產業的有學識者 (KOL)的見解

第12章 附錄

  • 調查手法

第13章:DelveInsight的服務內容

第14章 免責聲明

第15章 關於DelveInsight

目錄
Product Code: DIEI0853

DelveInsight's 'Treatment-resistant depression (TRD)- Epidemiology Forecast-2030' report delivers an in-depth understanding of the Treatment-resistant depression, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Treatment-resistant depression (TRD) Disease Understanding

Treatment-resistant depression (TRD) is a major depressive disorder (MDD) that does not respond to traditional and first-line therapeutic options. MDD is a mood disorder that causes a persistent feeling of sadness and loss of interest, which can interfere with day-to-day life. Depression lasting at least 2 weeks along with meeting about five or more of the DSM-V criteria (of MDD) is considered as MDD.

Several definitions exist, but there is a lack of consensus on a universally accepted operational definition of TRD. However, each model is an inadequate response to at least two different classes of antidepressant pharmacotherapies, even with adequate adherence to the treatment at optimum dosage for sufficient duration.

Various demographic factors such as female gender, old age, lower education level and economic status, and presence of life stressors have been associated with poor treatment response. Along with this, comorbid medical conditions such as endocrinopathies, immune-mediated, neurologic, autoimmune, and psychiatric conditions increase the likelihood of poor response to treatment. The pathophysiology of TRD is poorly understood, but it is thought to be multifactorial.

Adults with TRD bear a heavy burden of disease. According to recent literature reviews, adults with TRD as compared with those with treatment-responsive depression tend to have longer episodes of depression, more previous psychiatric hospital admissions, higher symptom severity, and a greater risk of comorbid anxiety disorders. Various symptoms experienced by children include Guilt, feeling of emptiness, self-dislike, sense of failure, self-denigration, quality of mood, fears, and phobias, suicidal attempts, etc.

Several factors create obstacles to adequate treatment of depression in the elderly. Medical co-morbidity, being very common in the elderly, may mask the depressive illness or lead medical practitioners to conclude that the symptoms of lowered mood are a component of the physical disorder. Elderly depressed patients may present with somatic complaints, such as pain, anorexia, or constipation, and lead to unnecessary physical investigations while neglecting the psychological symptoms. Memory problems and concentration difficulties may be the presenting complaints, and these may result in a misdiagnosis of dementia; this has been referred to as pseudodementia.

Treatment-resistant depression (TRD) Epidemiology

The Treatment-resistant depression epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Treatment-resistant depression epidemiology segmented as the Total diagnosed Prevalent of Treatment-resistant depression, Gender-specific cases, Age-specific cases. The report includes the Prevalent scenario of Treatment-resistant depression symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Treatment-resistant depression (TRD) Epidemiology

The epidemiology segment also provides the Treatment-resistant depression (TRD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

The total diagnosed prevalent population of Treatment-resistant depression Associated in 7MM countries estimated to be 4,464,781 cases in 2017.

  • As per the estimates, the United States has the highest Prevalent population of Treatment-resistant depression with 3,083,238 cases in 2017.
  • Among the EU5 countries, the UK had the highest Prevalent population of Treatment-resistant depression. On the other hand, Italy had the lowest Prevalent population with 45,641 in 2017.

Scope of the Report:

  • Treatment-resistant depression (TRD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • Treatment-resistant depression (TRD) Epidemiology Report and Model provide an overview of the risk factors and global trends of Treatment-resistant depression (TRD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Treatment-resistant depression (TRD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Treatment-resistant depression
  • The report provides the segmentation of the Treatment-resistant depression (TRD) epidemiology by Prevalent Cases of Treatment-resistant depression (TRD) in 7MM
  • The report provides the segmentation of the Treatment-resistant depression (TRD) epidemiology by Gender-specific Prevalent Cases of Treatment-resistant depression (TRD) in 7MM
  • The report provides the segmentation of the Treatment-resistant depression (TRD) epidemiology by Age-specific Prevalent Cases of Treatment-resistant depression (TRD) in 7MM

Report Highlights:

  • 11-Year Forecast of Treatment-resistant depression (TRD) epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Treatment-resistant depression (TRD)
  • Prevalent Cases according to segmentation: Gender-specific Prevalence of Treatment-resistant depression (TRD)
  • Prevalent Cases according to segmentation: Age-specific Prevalence of Treatment-resistant depression (TRD)

KOL- Views

We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Treatment-resistant depression (TRD)?
  • What are the key findings of the Treatment-resistant depression (TRD) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Treatment-resistant depression (TRD) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What are the disease risk, burden, and unmet needs of the Treatment-resistant depression?
  • What are the currently available treatments of Treatment-resistant depression?

Reasons to buy:

The Treatment-resistant depression (TRD) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Treatment-resistant depression (TRD) market
  • Quantify patient populations in the global Treatment-resistant depression (TRD) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Treatment-resistant depression (TRD) therapeutics in each of the markets covered
  • Understand the magnitude of Treatment-resistant depression (TRD) population by its Prevalence cases
  • Understand the magnitude of Treatment-resistant depression (TRD) population by its Gender-specific cases
  • Understand the magnitude of Treatment-resistant depression (TRD) population by its Age-specific cases
  • The Treatment-resistant depression (TRD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Treatment-resistant depression (TRD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

The estimated 12-month prevalence of DSM-IV MDE is lower in Italy and Germany with 3.0 ± 0.2%; followed by Spain as 4.0 ± 0.3%, and highest in France with 5.9 ± 0.6%. The average age of onset ascertained retrospectively was 25.7 in the high-income countries and women have a twofold increased risk of MDE compared with men. The patient pool was further analyzed with age categorization such as 18-34, 35-49, 50-64, and 65+. Among this age categorization, the occurrence of MDD has increased with increasing age, however, it has decreased in the older age group after 65 years. (Bromet E et al.)

Table of Contents

1. Key Insights

2. Treatment-Resistant Depression: Epidemiology Overview at a Glance

  • 2.1. Patient Share (%) Distribution of Treatment-Resistant Depression in 2017
  • 2.2. Patient Share (%) Distribution of Treatment-Resistant Depression in 2030

3. Organizations

4. Executive Summary

5. Disease Overview: Treatment-Resistant Depression

  • 5.1. Introduction
  • 5.2. Signs and Symptoms
  • 5.3. Causes and Risk factors
  • 5.4. Pathophysiology of depression
  • 5.5. Genetic Basis of Major Depressive Disorder
  • 5.6. Treatment Refractory Depression: Staging
  • 5.7. Diagnosis
    • 5.7.1. The Diagnostic and Statistical Manual of Mental Disorders (DSM)
    • 5.7.2. DSM-IV-TR Criteria for Major Depressive Disorder
    • 5.7.3. DSM-V: Diagnostic Criteria - Major depressive disorder
    • 5.7.4. Diagnostic Features
    • 5.7.5. Differential Diagnosis
    • 5.7.6. Diagnostic Criteria of Major Depressive Disorder According to ICD-10

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Diagnosed Prevalent Patient Population of Treatment-Resistant Depression
  • 6.3. Country Wise-Epidemiology of Treatment-Resistant Depression
  • 6.4. United States
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the US
    • 6.4.3. Gender-Specific Cases of Treatment-Resistant Depression in the United States
    • 6.4.4. Age-Specific Cases of Treatment-Resistant Depression in the United States
  • 6.5. EU5
    • 6.5.1. Assumptions and Rationale
  • 6.6. Germany
    • 6.6.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Germany
    • 6.6.2. Gender-Specific Cases of Treatment-Resistant Depression in Germany
    • 6.6.3. Age-Specific Cases of Treatment-Resistant Depression in Germany
  • 6.7. France
    • 6.7.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in France
    • 6.7.2. Gender-Specific Cases of Treatment-Resistant Depression in France
    • 6.7.3. Age-Specific Cases of Treatment-Resistant Depression in France
  • 6.8. Italy
    • 6.8.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Italy
    • 6.8.2. Gender-Specific Cases of Treatment-Resistant Depression in Italy
    • 6.8.3. Age-Specific Cases of Treatment-Resistant Depression in Italy
  • 6.9. Spain
    • 6.9.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Spain
    • 6.9.2. Gender-Specific Cases of Treatment-Resistant Depression in Spain
    • 6.9.3. Age-Specific Cases of Treatment-Resistant Depression in Spain
  • 6.10. United Kingdom
    • 6.10.1. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the UK
    • 6.10.2. Gender-Specific Cases of Treatment-Resistant Depression in the United Kingdom
    • 6.10.3. Age-Specific Cases of Treatment-Resistant Depression in the United Kingdom
  • 6.11. Japan
    • 6.11.1. Assumptions and Rationale
    • 6.11.2. Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Japan
    • 6.11.3. Gender-Specific Cases of Treatment-Resistant Depression in Japan
    • 6.11.4. Age-Specific Cases of Treatment-Resistant Depression in Japan

7. Current Treatment Practices

  • 7.1. Treatment Strategies for TRD
  • 7.2. NICE guideline: Depression in adults; treatment and management
  • 7.3. French clinical guideline: Treatment-Resistant Depression

8. Unmet Needs

17. SWOT Analysis

19. Case studies

  • 19.1. Complex Case Study: Treatment-Resistant Depression
  • 19.2. Successful Treatment of a patient with low doses of Ketamine intravenous Injection: A Case Study
  • 19.3. A Case Study: Remission of treatment-resistant depression with electroconvulsive therapy

20. KOL Views

21. Appendix

  • 21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Tables

  • Table 1: Thase and Rush Staging Method
  • Table 2: Thase and Rush Staging Method
  • Table 3: The European Staging Method
  • Table 4: Massachusetts General Hospital Staging Method
  • Table 5: Major Depressive Disorder Diagnostic Criteria according to DSM-IV-TR
  • Table 6: Depressive Episode Criteria (maybe part of Major Depressive Disorder or isolated episode)
  • Table 7: DSM-IV-TR diagnostic criteria - MDD
  • Table 8: DSM-IV-TR diagnostic criteria for MDD, Recurrent
  • Table 9: Selected DSM-IV-TR Major Depressive Episode Specifier
  • Table 10: Major depressive disorder diagnostic criteria according to DSM-V
  • Table 11: Severity/course specifier
  • Table 12: Prevalent Patient Population of Treatment-Resistant Depression in 7MM (2017-2030)
  • Table 13: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the United States (2017-2030)
  • Table 14: Gender-Specific Cases of Treatment-Resistant Depression in the United States (2017-2030)
  • Table 15: Age-Specific Cases of Treatment-Resistant Depression in the United States (2017-2030)
  • Table 16: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Germany (2017-2030)
  • Table 17: Gender-Specific Cases of Treatment-Resistant Depression in Germany (2017-2030)
  • Table 18: Age-Specific Cases of Treatment-Resistant Depression in Germany (2017-2030)
  • Table 19: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in France (2017-2030)
  • Table 20: Gender-Specific Cases of Treatment-Resistant Depression in France (2017-2030)
  • Table 21: Age-Specific Cases of Treatment-Resistant Depression in France (2017-2030)
  • Table 22: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Italy (2017-2030)
  • Table 23: Gender-Specific Cases of Treatment-Resistant Depression in Italy (2017-2030)
  • Table 24: Age-Specific Cases of Treatment-Resistant Depression in Italy (2017-2030)
  • Table 25: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Spain (2017-2030)
  • Table 26: Gender-Specific Cases of Treatment-Resistant Depression in Spain (2017-2030)
  • Table 27: Age-Specific Cases of Treatment-Resistant Depression in Spain (2017-2030)
  • Table 28: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the United Kingdom (2017-2030)
  • Table 29: Gender-Specific Cases of Treatment-Resistant Depression in the United Kingdom (2017-2030)
  • Table 30: Age-Specific Cases of Treatment-Resistant Depression in the United Kingdom (2017-2030)
  • Table 31: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Japan (2017-2030)
  • Table 32: Gender-Specific Cases of Treatment-Resistant Depression in Japan (2017-2030)
  • Table 33: Age-Specific Cases of Treatment-Resistant Depression in Japan (2017-2030)

List of Figures

  • Figure 1: Signs and Symptoms of Treatment-Resistant Depression
  • Figure 2: Differential Diagnosis
  • Figure 3: Total Diagnosed Prevalent Patient Population of TRD in 7MM (2017-2030)
  • Figure 4: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in the US (2017-2030)
  • Figure 5: Gender-Specific Cases of Treatment-Resistant Depression in the United States (2017-2030)
  • Figure 6: Age-Specific Cases of Treatment-Resistant Depression in the United States (2017-2030)
  • Figure 7: Total Diagnosed Prevalent Cases of TRD in Germany (2017-2030)
  • Figure 8: Gender-Specific Cases of Treatment-Resistant Depression in Germany (2017-2030)
  • Figure 9: Age-Specific Cases of Treatment-Resistant Depression in Germany (2017-2030)
  • Figure 10: Total Diagnosed Prevalent Cases of TRD in France (2017-2030)
  • Figure 11: Gender-Specific Cases of Treatment-Resistant Depression in France (2017-2030)
  • Figure 12: Age-Specific Cases of Treatment-Resistant Depression in France (2017-2030)
  • Figure 13: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Italy (2017-2030)
  • Figure 14: Gender-Specific Cases of Treatment-Resistant Depression in Italy (2017-2030)
  • Figure 15: Age-Specific Cases of Treatment-Resistant Depression in Italy (2017-2030)
  • Figure 16: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Spain (2017-2030)
  • Figure 17: Gender-Specific Cases of Treatment-Resistant Depression in Spain (2017-2030)
  • Figure 18: Age-Specific Cases of Treatment-Resistant Depression in Spain (2017-2030)
  • Figure 19: Total Diagnosed Prevalent Cases of TRD in the UK (2017-2030)
  • Figure 20: Gender-Specific Cases of TRD in the United Kingdom (2017-2030)
  • Figure 21: Age-Specific Cases of Treatment-Resistant Depression in the United Kingdom (2017-2030)
  • Figure 22: Total Diagnosed Prevalent Cases of Treatment-Resistant Depression in Japan (2017-2030)
  • Figure 23: Gender-Specific Cases of Treatment-Resistant Depression in Japan (2017-2030)
  • Figure 24: Age-Specific Cases of Treatment-Resistant Depression in Japan (2017-2030)
  • Figure 25: Recommendations for Switching ADT
  • Figure 26: Unmet Needs